Begümhan Demir Gündoğan*

Professor, Department of Pediatric Oncology, Mersin University, Los Angeles, USA

*Corresponding Author: Begümhan Demir Gündoğan, Professor, Department of Pediatric Oncology, Mersin University, Los Angeles, USA.

Received: December 24, 2021; Published: February 04, 2022

Abstract

Sinusoidal obstruction syndrome (SOS) is a life-threatening complication that usually develops as a result of conditioning regimens for hematopoietic stem cell transplantation (HSCT). It is also less diagnosed after the use of chemotherapeutic agents, removal of alkaloid toxins, high-dose radiation therapy, or liver transplantation. It presents with hepatomegaly, right upper quadrant pain, jaundice and ascites [1-3]. Outside of the HSCT setting, only a few cases of SOS with Wilms tumor, rhabdomyosarcoma, acute lymphoblastic leukemia, and medulloblastoma have been reported. Here, we wanted to present our experience in 5 pediatric cases with SOS due to conventional treatment.

Keywords: Veno-Occlusive Disease; Hematopoetic Stem Cell Transplantation; Child

References

1. Mohty M., et al. “Sinusoidal obstruction syndrome/Venoocclusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)”. Bone Marrow Transplant 50 (2015): 781-789.
2. Chao N. “How I treat sinusoidal obstruction syndrome”. Blood 123 (2014): 4023-4026.
3. Richardson PG., et al. “Defibrotide sodium for the treatment of hepatic Venoocclusive disease/sinusoidal obstruction syndrome”. Expert Review of Clinical Pharmacology 11 (2018): 113-124.
4. Cefalo MG., et al. “Hepatic Venoocclusive disease: a chemotherapy-related toxicity in children with malignancies”. Paediatric Drugs 12 (2010): 277-284.
5. Richardson PG., et al. “Defibrotide sodium for the treatment of hepatic Venoocclusive disease/sinusoidal obstruction syndrome”. Expert Review of Clinical Pharmacology 11 (2018): 113-124.
6. Richardson PG., et al. “Phase 3 trial of defibrotide for the treatment of severe Venoocclusive disease and multi-organ failure”. Blood 127 (2016): 1656-1664.
7. Carreras E., et al. “The incidence of Venoocclusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade”. Blood Marrow Transplant11 (2011): 1713-1720.
8. Bearman SI. “The syndrome of hepatic Venoocclusive disease after marrow transplantation”. Blood 11 (1995): 3005-3020.
9. Corbacioglu S., et al. “Diagnosis and severity criteria for sinusoidal obstruction syndrome/venoocclusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation”. Bone Marrow Transplant 53 (2018): 138-145.
10. Faraci M., et al. “Sinusoidal Obstruction Syndrome/Venoocclusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association Hematopoietic Stem Cell Transplantation Group”. Biology of Blood Marrow Transplant 25 (2019): 313-320.
11. Kallianpur AR., et al. “The hemochromatosis C282Y allele: a risk factor for hepatic Venoocclusive disease after hematopoietic stem cell transplantation”. Bone Marrow Transplant 35 (2005): 1155-1164.
12. Efrati E., et al. “MTHFR C677T/A1298C genotype: a possible risk factor for liver sinusoidal obstruction syndrome”. Bone Marrow Transplant 49 (2014): 726-727.
13. Srivastava A., et al. “Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation”. Blood 104 (2004): 1574-1577.
14. Jones RJ., et al. “Venoocclusive disease of the liver following bone marrow transplantation”. Transplantation 44 (1987): 778-783.
15. McDonald GB., et al. “Venoocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors”. Hepatology 4 (1984): 116-122.
16. Dignan FL., et al. “BCSH/BSBMT guideline: diagnosis and management of Venoocclusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation”. British Journal of Haematology 163 (2013): 444-457.
17. Helmy A. “Review article: updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome”. Alimentary Pharmacology and Therapeutics 23 (2006): 11-25.
18. DeLeve LD and Wang X. “Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes”. Pharmacology 60 (2000): 143-154.
19. Richardson P and Guinan E. “Hepatic Venoocclusive disease following hematopoietic stem cell transplantation”. Acta Haematology 106 (2001): 57-68.

Citation

Citation: Begümhan Demir Gündoğan. “Chemotherapy Induced Sinusoidal Obstruction Syndrome in Children”. Acta Scientific Paediatrics 5.3 (2022): 34-38.

Copyright

Copyright: © 2022 Begümhan Demir Gündoğan. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.